ViTToria Biotherapeutics
Vittoria Biotherapeutics pioneers in gene-edited T-cell therapies, enhancing efficacy and safety in cell-based treatments.
Founded
2021Vittoria Biotherapeutics pioneers in gene-edited T-cell therapies, enhancing efficacy and safety in cell-based treatments.
Founded with a mission to revolutionize cell therapy, ViTToria Biotherapeutics focuses on developing gene-edited T-cell therapeutics to address unmet medical needs in oncology and autoimmune diseases. Their core technology, Senza5™, aims to improve the efficacy, safety, and utility of cell-based treatments. By leveraging cutting-edge advancements in gene editing, ViTToria Biotherapeutics is committed to providing next-generation solutions that shift paradigms in medical treatment.
Key figures affiliated with ViTToria Biotherapeutics include field-leading pioneers in cell therapy and gene editing. The company has garnered attention for its innovative Senza5™ technology, which has shown promising results in preclinical settings. ViTToria Biotherapeutics' impact is marked by its potential to significantly enhance the effectiveness and safety of T-cell therapies, offering new hope for patients with challenging medical conditions.
Companies similar to ViTToria Biotherapeutics include Vita Therapeutics, Vineti, Affini-T Therapeutics and Spotlight Therapeutics.
ViTToria Biotherapeutics was founded in 2021.
ViTToria Biotherapeutics' headquarters is located in Philadelphia, PA, US.
ViTToria Biotherapeutics' most recent funding round was for $15M (USD) in November 2023.
As of Nov 14, 2023, ViTToria Biotherapeutics has disclosed funding of $25M (USD). Undisclosed round amounts are excluded.
ViTToria Biotherapeutics has 34 employees as of Feb 5, 2024.
Spotlight Therapeutics
spotlighttx.com
